Vimarsana
Biggest News Aggregation in the World

Page 3 - Software Pro News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Software Pro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Software Pro Today - Breaking & Trending Today

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements - Vimarsana News

Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements

Agilent Technologies Inc. today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis... | June 6, 2023

The Top Software Development & Software Testing Companies In June, According To DesignRush - Vimarsana News

The Top Software Development & Software Testing Companies In June, According To DesignRush

MIAMI, FL (PRWEB) June 02, 2023 -- Companies are now increasingly making efforts to implement the latest trends and achieve digital transformation in order to

Source: prweb.com
The Top Cybersecurity Companies In April, According To DesignRush - Vimarsana News

The Top Cybersecurity Companies In April, According To DesignRush

MIAMI, FL (PRWEB) April 27, 2023 -- According to Statista, 71% of organizations were victimized by ransomware in 2022, the highest figure ever reported. It

Source: prweb.com
The Top Software Development & Software Testing Companies In April, According To DesignRush - Vimarsana News

The Top Software Development & Software Testing Companies In April, According To DesignRush

MIAMI, FL (PRWEB) April 13, 2023 -- The global business software and service market size was estimated at $474.61 billion in 2022. It is projected to further

Source: prweb.com
Building a CAR-T Toolbox for More Comprehensive Assessment of Cell Therapies - Vimarsana News

Building a CAR-T Toolbox for More Comprehensive Assessment of Cell Therapies

Scientists developing chimeric antigen receptor (CAR) T cell products strive to maximize specificity, potency, and persistence of these therapies, but the inability to predict treatment efficacy and response remains a significant challenge. Daniel Hui, PhD, Associate Director of Analytical Development at Tmunity Therapeutics, addresses these challenges and highlights the company’s multiplatform approach to build an innovative “toolbox” of orthogonal assays to provide a comprehensive set of data to characterize CAR-T cell therapeutic products.